Brief: Dyadic International Says Advancing Proprietary Owned Covid-19 Vaccine Candidate, Dyai-100, Towards Human Clinical Trial
29/03/2021 13:48
March 29 (Reuters) - Dyadic International Inc DYAI.O :
* UPDATE -- DYADIC ADVANCING PROPRIETARY OWNED COVID-19
VACCINE
CANDIDATE, DYAI-100, TOWARDS HUMAN CLINICAL TRIAL
Source text for Eikon: ID:nGNX9lcqsS
Further company coverage: DYAI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Dyadic International
See all newsDyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic International - Develops C1 Cell Lines And Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days
Brief: Dyadic Announces Continued Listing On The Nasdaq Capital Market
Brief: Dyadic And Scripps Research Collaborate On Rapid-Response Hantavirus Antibody And Vaccine Development